JP2022544053A5 - - Google Patents
Info
- Publication number
- JP2022544053A5 JP2022544053A5 JP2022505598A JP2022505598A JP2022544053A5 JP 2022544053 A5 JP2022544053 A5 JP 2022544053A5 JP 2022505598 A JP2022505598 A JP 2022505598A JP 2022505598 A JP2022505598 A JP 2022505598A JP 2022544053 A5 JP2022544053 A5 JP 2022544053A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- pharmaceutical composition
- gene therapy
- administration
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880240P | 2019-07-30 | 2019-07-30 | |
| US62/880,240 | 2019-07-30 | ||
| US16/943,849 US20210032333A1 (en) | 2019-07-30 | 2020-07-30 | Methods and Compositions for Reducing Immunogenicity By Non-Depletional B Cell Inhibitors |
| PCT/US2020/044312 WO2021022072A1 (en) | 2019-07-30 | 2020-07-30 | Methods and compositions for reducing immunogenicity by non-depletional b cell inhibitors |
| US16/943,849 | 2020-07-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022544053A JP2022544053A (ja) | 2022-10-17 |
| JP2022544053A5 true JP2022544053A5 (https=) | 2025-07-10 |
Family
ID=74230561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022505598A Ceased JP2022544053A (ja) | 2019-07-30 | 2020-07-30 | 非枯渇性ｂ細胞阻害剤によって免疫原性を低下させるための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210032333A1 (https=) |
| JP (1) | JP2022544053A (https=) |
| KR (1) | KR20220091458A (https=) |
| AU (1) | AU2020323596A1 (https=) |
| BR (1) | BR112022001699A2 (https=) |
| CA (1) | CA3149209A1 (https=) |
| IL (1) | IL290134A (https=) |
| MX (1) | MX2022001080A (https=) |
| WO (1) | WO2021022072A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| EP4004052A4 (en) * | 2019-07-30 | 2023-11-01 | Provention Bio, Inc. | METHODS AND COMPOSITIONS FOR REDUCING IMMUNOGENICITY BY NON-DEPLETED B CELL INHIBITORS |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| EP4453040A4 (en) * | 2021-12-23 | 2025-12-24 | Provention Bio Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF BARTH'S SYNDROME |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ573646A (en) * | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| UA116479C2 (uk) * | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
| WO2017214096A1 (en) * | 2016-06-07 | 2017-12-14 | Macrogenics, Inc. | Methods for the use of cd32b x cd79b-binding molecules in the treatment of inflammatory diseases and disorders |
| IL269150B2 (en) * | 2017-03-16 | 2025-04-01 | Innate Pharma | Cancer treatment preparations and methods |
-
2020
- 2020-07-30 MX MX2022001080A patent/MX2022001080A/es unknown
- 2020-07-30 BR BR112022001699A patent/BR112022001699A2/pt unknown
- 2020-07-30 JP JP2022505598A patent/JP2022544053A/ja not_active Ceased
- 2020-07-30 AU AU2020323596A patent/AU2020323596A1/en active Pending
- 2020-07-30 US US16/943,849 patent/US20210032333A1/en not_active Abandoned
- 2020-07-30 KR KR1020227006543A patent/KR20220091458A/ko not_active Ceased
- 2020-07-30 WO PCT/US2020/044312 patent/WO2021022072A1/en not_active Ceased
- 2020-07-30 CA CA3149209A patent/CA3149209A1/en active Pending
-
2022
- 2022-01-26 IL IL290134A patent/IL290134A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022544053A5 (https=) | ||
| Lefrancois | Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo | |
| CN101679516B (zh) | 靶向金黄色葡萄球菌ORF0657n的抗原结合蛋白 | |
| JP7164530B2 (ja) | Ｉｌ－４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 | |
| JP2024156992A (ja) | 関節リウマチの治療 | |
| CA3148621A1 (en) | Compositions and methods comprising protease-activated therapeutic agents | |
| JP6371222B2 (ja) | インフルエンザの受動免疫用抗体 | |
| CN115043938B (zh) | SARS-CoV-2及其突变株的抗体及应用 | |
| JP2022160685A5 (https=) | ||
| Gregoriou et al. | Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial | |
| JP2024520666A5 (https=) | ||
| ES2992409T3 (es) | Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17 | |
| Dibo et al. | Antibody therapy for the control of viral diseases: An update | |
| US20240366597A1 (en) | Cancer treatment combinations | |
| KR20170020423A (ko) | 항-hsv 항체의 국소 적용 | |
| JP2024511970A5 (https=) | ||
| Bottermann et al. | Virus neutralisation by intracellular antibodies | |
| Shcheblyakov et al. | Development and characterization of two GP-specific monoclonal antibodies, which synergistically protect non-human primates against Ebola lethal infection | |
| Salah et al. | Targeted therapies: the role of monoclonal antibodies in disease management | |
| JP2020502218A5 (https=) | ||
| JP2022514561A5 (https=) | ||
| Talotta et al. | Therapeutic peptides for the treatment of systemic lupus erythematosus: a place in therapy | |
| RU2024120541A (ru) | Способы и композиции для лечения синдрома барта | |
| Bahadir et al. | Monoclonal Antibodies for Pediatric Viral Disease Prevention and Treatment | |
| US11440951B2 (en) | Therapeutic antibodies to Marburg virus |